DATA GRAPHICS | Data Byte
After a period of rapid growth, sales of all three approved SMA products have stabilized in recent quarters
By Selina Koch, Executive Editor, and Gunjan Ohri, Data Content Analyst
November 18, 2023 12:45 AM UTC
Following a rapid growth trajectory, sales of Roche’s spinal muscular atrophy therapy Evrysdi appear to be joining those of Biogen’s Spinraza and Novartis’ Zolgensma in flattening out. Spinraza, the oldest of the three medicines, remains the market leader.
Sales of Evrysdi risdiplam from Roche (SIX:ROG; OTCQX:RHHBY) climbed from $9 million in 3Q20, its first quarter on the market, to $397 million in 1Q23 and have since held steady, coming in at $394 million in 3Q23…